Novavax Inc. Common Stock (NVAX)
Stock · NASDAQ · Health Care
$11.25as of 10/16/2026
Price chart
Active signals
NVAX Signal Track Record
How signals performed across all stocks →What NVAX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -3.3% | 46% | October 5, 2026 |
| Bollinger Band Breakdown | 23 | -8.1% | 35% | July 14, 2026 |
| Bollinger Band Breakout | 21 | -11.8% | 24% | October 9, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +4.0% | 50% | August 20, 2026 |
| Any 20-session window (baseline) | -4.1% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Ser…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 749
- Website
- www.novavax.com/?locale=US
Fundamentals
- 1-day range
- $12.19$13.25
- Market cap
- $1.27B
- P/E (trailing)
- —
- P/E (forward)
- -78.21
- EPS (trailing)
- $-1.54
- Dividend yield
- —
- Beta
- 2.81
- Avg. volume
- 5.75M
- Dividend pay date
- May 10, 2019
How Novavax Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Novavax Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NVAXNovavax Inc. Common Stock$11.26▼ 12.17%Market cap $1.27BP/E —$6.2$13.39
- IMTXImmatics N.V. Ordinary Shares$6.73▼ 5.74%Market cap $1.26BP/E —$6.73$12.41
- VORVor Biopharma Inc. Common Stock$18.03▼ 6.77%Market cap $1.28BP/E 1.82$6.5$33.42
- INBXInhibrx Biosciences Inc. Common Stock$89.83▼ 0.74%Market cap $1.26BP/E —$28.16$155.29
- GLUEMonte Rosa Therapeutics Inc. Common Stock$9.74▼ 3.75%Market cap $1.33BP/E —$8.94$25.77
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NVAX Novavax Inc. Common Stock | $1.27B | — | $11.26 | ▼ 12.17% | $6.2$13.39 |
| IMTX Immatics N.V. Ordinary Shares | $1.26B | — | $6.73 | ▼ 5.74% | $6.73$12.41 |
| VOR Vor Biopharma Inc. Common Stock | $1.28B | 1.82 | $18.03 | ▼ 6.77% | $6.5$33.42 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.26B | — | $89.83 | ▼ 0.74% | $28.16$155.29 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.33B | — | $9.74 | ▼ 3.75% | $8.94$25.77 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine PushYahoo · 10/10/2026
- Sector Update: Healthcare Stocks Gain Late AfternoonYahoo · 10/9/2026
- Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech RalliesYahoo · 10/9/2026
- Sector Update: Healthcare Stocks Gain Friday AfternoonYahoo · 10/9/2026
- Moderna stock hits 4-year high on planned national cancer vaccine effortYahoo · 10/9/2026
- A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock RallyBenzinga · 10/9/2026
- Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowYahoo · 10/9/2026
- Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York TimesBenzinga · 10/9/2026
- 'Russia Denies Report of Second Case of Illness in Siberia' - Bloombergbenzinga · 10/8/2026
Insider Activity
Insider Actions →- Richard J. Rodgers · June 20, 2026 · Option Exercise18.9K
- King Rachel K. · June 20, 2026 · Option Exercise18.9K
- Richard Douglas · June 20, 2026 · Option Exercise18.9K
- MCGLYNN MARGARET G · June 20, 2026 · Option Exercise18.9K
- MOTT DAVID M · June 20, 2026 · Option Exercise18.9K
- Alton Gregg H · June 20, 2026 · Option Exercise18.9K
- MCGLYNN MARGARET G · June 18, 2026 · Grant21.3K
- MOTT DAVID M · June 18, 2026 · Grant14.2K
- MOTT DAVID M · June 18, 2026 · Grant21.3K
- Alton Gregg H · June 18, 2026 · Grant14.2K
- Richard J. Rodgers · June 18, 2026 · Grant14.2K
- Richard J. Rodgers · June 18, 2026 · Grant21.3K
- King Rachel K. · June 18, 2026 · Grant14.2K
- King Rachel K. · June 18, 2026 · Grant21.3K
- Richard Douglas · June 18, 2026 · Grant14.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 118.48M
- Total value held
- $958.47M
- Institutional holders
- 253
- Unknown14.85M
- Unknown12.84M
- Unknown8.97M
- Unknown8.09M
- Unknown7.13M
- Unknown6.88M
- Unknown6.64M
- Unknown4.48M
- Unknown3.90M
- Unknown3.88M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports
Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports. Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.